Status:
COMPLETED
Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients
Lead Sponsor:
FMH College of Medicine and Dentistry
Conditions:
Covid19
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
Background: The first case of Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were diagnosed in Wuhan, China in 2019. In the first half of 2020 this disease has already co...
Detailed Description
The first case of Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were diagnosed in Wuhan, China in 2019. In the first half of 2020 this disease has already converted into ...
Eligibility Criteria
Inclusion
- All patients diagnosed with COVID-19 infection with positive reverse transcriptase RT-PCR test, who were willing to participate in this study
- Patients having age of 18-75 years
- Patients of both genders male and female
- Patients who had mild symptoms of Corona virus disease and RT- PCR positive for SARS-Cov-2
- Ability to take oral medication and were willing to adhere to the drug intake regimen
Exclusion
- Known severe allergic reactions to Ivermectin
- Pregnancy or breastfeeding
- Severe symptoms likely attributed to Cytokine Release Storm
- Malignant diseases
- Chronic kidney disease
- Cirrhosis liver with Child class B or C
Key Trial Info
Start Date :
May 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2020
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04739410
Start Date
May 1 2020
End Date
June 30 2020
Last Update
February 4 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Aijaz Zeeshan Khan Chachar
Lahore, Punjab Province, Pakistan, 54000